Fredun Pharmaceuticals Faces ₹13.21 Crore Preferential Issue Utilization Deviations

CareEdge flagged ₹13.21 crore of preferential-issue proceeds used outside explicitly defined objects, commingling, unsupported ₹1.50 crore R&D documentation, and inconsistent balances. It reported ₹79.80 crore utilized and ₹31.73 crore unutilized versus company/CA figures of ₹77.15 crore and ₹21.47 crore. Context: extends prior fund-utilisation control concerns.